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TIP39 (‘‘tuberoinfundibular peptide of 39 residues”) acts via the parathyroid hormone 2 receptor, PTH2, a
Family B G protein-coupled receptor (GPCR). Despite the importance of GPCRs in human physiology and
pharmacotherapy, little is known about the molecular details of the TIP39-PTH2 interaction. To address
this, we utilised the different pharmacological profiles of TIP39 and PTH(1–34) at PTH2 and its related
receptor PTH1: TIP39 being an agonist at the former but an antagonist at the latter, while PTH(1–34) acti-
vates both. A total of 23 site-directed mutations of PTH2, in which residues were substituted to the equiv-
alent in PTH1, were made and pharmacologically screened for agonist activity. Follow-up mutations were
analysed by radioligand binding and cAMP assays. A model of the TIP39-PTH2 complex was built and
analysed using molecular dynamics. Only Tyr318-Ile displayed reduced TIP39 potency, despite having
increased PTH(1–34) potency, and further mutagenesis and analysis at this site demonstrated that this
was due to reduced TIP39 affinity at Tyr318-Ile (pIC50 = 6.01 ± 0.03) compared with wild type
(pIC50 = 7.81 ± 0.03). The hydroxyl group of the Tyr-3180s side chain was shown to be important for
TIP39 binding, with the Tyr318-Phe mutant displaying 13-fold lower affinity and 35-fold lower potency
compared with wild type. TIP39 truncated by up to 5 residues at the N-terminus was still sensitive to the
mutations at Tyr-318, suggesting that it interacts with a region within TIP39(6–39). Molecular modelling
and molecular dynamics simulations suggest that the selectivity is based on an interaction between the
Tyr-318 hydroxyl group with the carboxylate side chain of Asp-7 of the peptide.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The recent increase in structural information for class B GPCRs,
encompassing both the extracellular domain and the transmem-
brane helical bundle, can be used to interpret pharmacological
studies of class B peptide hormones. Here our focus is on the
parathyroid hormone 2 receptor (PTH2), a Family B G protein-
coupled receptor (GPCR) which is potently activated by its endoge-
nous neuropeptide TIP39 (‘‘tuberoinfundibular peptide of 39
residues”). Human PTH2 is also activated by parathyroid hormone
(PTH) and indeed shares 50% sequence identity with PTH1, thereceptor for both PTH and PTH-related peptide (PTHrP), which is
why PTH2 was named after PTH. However, TIP39, acting through
PTH2, has very distinct physiological roles compared with the cal-
cium homeostasis function of PTH acting through PTH1 – for exam-
ple, TIP39 modulates various aspects of the stress response, and is
also involved in thermoregulation, nociception, and prolactin
release [1]. Here we seek to identify the key interactions that gov-
ern the selective activation of PTH2 by TIP39.
Like other Family B GPCRs, PTH2 is activated by peptide agonists
via a two site interaction model [2,3] in which the ligand’s
C-terminal a-helical region interacts with the receptor’s
N-terminal extracellular (N) domain to generate affinity, while
the N-terminal region of the peptide activates the receptor via a
second interaction with the receptor’s transmembrane helices
and connecting loops (juxta-membrane ‘‘J” domain). The nature
of the first interaction has been detailed via the solution of theeceptor
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X-ray crystallography [4]. The crystal structure showed that the
ligand forms an a-helix which docks into a long hydrophobic
groove on the N domain via hydrophobic interactions formed by
Val-21⁄, Trp-23⁄, Leu-24⁄, Leu-28⁄, Val-31⁄ and Phe-34⁄ of PTH
(ligand residues will be distinguished from receptor residues by
an asterisk following the residue number). However, despite the
solution of the crystal structure of the isolated J domain of two
related family B GPCRs [5–7], the molecular details of the second
activating interaction remain to be determined due to the absence
of endogenous ligands in these structures. In the absence of a crys-
tal structure of a peptide-bound Family B GPCR, some insights into
how peptides bind to the J domain have nevertheless been gained
through protein chemical and molecular pharmacological
approaches. For example, the extreme N-terminal residues of both
PTH and PTHrP have each been replaced by benzoylphenylalanine
(BPA), and these active peptide agonist analogues have been cross-
linked to Met-425 of the receptor [8,9], with a model generated
which suggested that the N-terminus of PTH lies across the extra-
cellular surface of the receptor [8]. The cross-linking results were
later refined by use of disulphide trapping, which can be more
specific than BPA-based photoaffinity cross-linking, implying a
preference for contacts between the extreme N-terminus of PTH
with Leu-368, Try-421, Phe-424 and Met-425 [10]. The general
consensus at that time, which predated the X-ray structures of
the TM domain, was that class B receptors may bind peptides in
a variety of ways [11,12], and the peptide binding model based
upon the cysteine trapping data was only refined slightly from that
derived from the earlier BPA data, with the N-terminus of the pep-
tide interacting with the extracellular face of the TM domain,
rather than binding deeper into the core of the helical bundle.
While PTH is able to potently activate both human PTH1 and
PTH2 receptors, surprisingly PTHrP does not activate PTH2, despite
binding with moderate affinity. By using chimeric receptors and
modified peptide ligands, it has been shown that the features
responsible for the ability of PTH2 to select against PTHrP are due
to Ile-5⁄ and Trp-23⁄ of PTH being His-5⁄ and Phe-23⁄ in PTHrP
[13]. The high affinity of PTH at PTH2 is maintained in part by
the interaction between Trp-23⁄ of the peptide and Val-41 in the
N-domain of the receptor [4,14]. However, this interaction is
absent for PTHrP/PTH2 binding, due to the smaller size of Phe-
23⁄ [14], which results in lower affinity. The inability of PTHrP to
activate PTH2 is due to the presence of His-5⁄ in PTHrP, rather than
Ile-5⁄ in PTH, which has been functionally linked through two
reciprocal receptor studies to Ile-244 and Tyr-318 in the J domain
of PTH2 [13,15]. Interestingly, the two topologically equivalent
residues to Ile-244 and Tyr-318 in the glucagon receptor (Gln-
232 and Leu-307) can be found to be in close contact with each
other in the crystal structures of the latter [6,7]; see Fig. 1A for a
sequence alignment). In contrast to what has been previously sug-
gested for PTH [10], the location of Ile-244 and Tyr-318 within the
TM bundle implies that the N-terminus of PTH receptor ligands
may bind within the TM domain. This would be in line with what
has been suggested for peptide binding at the glucagon and GLP-1
receptors through detailed and extensive mutagenesis and mod-
elling studies [6,16–19].
Despite the success of the chimeric and single residue-swap
studies of PTH1 and PTH2 described above [13–15,20], which iden-
tified PTH/PTHrP binding and selectivity determinants at PTH1 and
PTH2, the nature of the TIP39 selection has not been explored to
the same degree. While TIP39 is a potent agonist at PTH2, it does
not activate PTH1, despite binding with moderate affinity [21]. Chi-
meric PTH1/PTH2 receptors have been used to demonstrate that the
J domain of PTH1 is responsible for selecting against the high affin-
ity binding of TIP39 and that this domain is likely to interact with
the N-terminal region of the ligand [21]. The truncation of the firstPlease cite this article in press as: R.E. Weaver et al., High affinity binding of
requires the hydroxyl group of Tyr-318 on transmembrane helix 5, Biochem. P6 residues of TIP39, to yield TIP (7–39), resulted in a peptide with
no efficacy at PTH2 but increased its affinity at PTH1 relative to
TIP39 [21], suggesting that selectivity for PTH2 activation is
encoded within the first 6 residues of peptide.
The aim of this study was to use site-directed mutagenesis to
substitute selected PTH2 residues in the J domain, with those found
in PTH1, in order to identify residues in PTH2 that play a role in
ligand selection through the recognition of the N-terminal region
of TIP39. To aid the interpretation of the data generated from the
study, and to resolve the argument as to whether the PTH receptor
ligands bind more deeply within the TM domain, we constructed a
3-dimensional model of PTH2 receptor bound with TIP39, based
upon previous models of agonist-bound GLP-1R, and analysed
the residues that could interact with Tyr-318 using all-atom
molecular dynamics simulations.2. Methods
2.1. Constructs
The full-length cDNA of human PTH1 and PTH2 (gift from
GlaxoSmithKline) in pcDNA3 (Invitrogen, Paisley, UK) were used
to express wild type receptors as described previously [14]. Mutant
PTH2 receptors were selected (Fig. 1) and generated using Quik-
Change site-directed mutagenesis (Stratagene, La Jolla, CA, USA)
and confirmed by DNA sequencing. These various pcDNA3 con-
structs were used to express the wild type human PTH1 and
PTH2 receptors, and mutant PTH2 receptors, in Human Embryonic
Kidney (HEK)-293 cells. Residues which were predicted to be close
to the extracellular ends of the TM regions of PTH2, and which were
not conserved between PTH1 and PTH2, were targeted for site-
directed mutagenesis.
2.2. Cell culture
The HEK-293 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM, from Sigma, Poole, UK) supplemented with 10%
foetal calf serum (LonzaWokinham Ltd., Wokingham, UK) and con-
taining 2 mM L-glutamine, 100 U/ml penicillin and 100 lg/ml
streptomycin (Invitrogen, Paisley, UK). Cells were transfected with
pcDNA3 containing the cDNA encoding the receptors, using the
SuperFect Transfection Reagent (Qiagen Ltd., Crawley, UK.) and
stable clones were selected with G418 antibiotic (Invitrogen, Pais-
ley, UK) as follows. Cells were seeded into a 25 cm2 flask containing
10 ml of media and transfected when they reached 50–80% conflu-
ence. To do this, 20 ll of SuperFect was mixed with a DNA solu-
tion consisting of 5 lg plasmid DNA in 150 ll DMEM. The DNA
was incubated with the reagent for 10 min at room temperature
after which 1 ml of media was then added and mixed gently. The
cells were washed once with sterile PBS (137 mM NaCl, 10 mM
Phosphate, 2.7 mM KCl, pH 7.4; Sigma, Poole, UK) before the trans-
fection mixture was added and incubated for 3 h at 37 C. The cells
were then washed 3 times with PBS before the addition of fresh
media. Three days later, the supernatant was removed and the cells
were washed with PBS before fresh media was added. Selection of
transfected cells was achieved by addition of 800 lg ml1 G418.
The media, containing G418, was replaced every 3 days until indi-
vidual colonies were clearly visible. Approximately 10–20 individ-
ual colonies were detached from the flask using trypsin, seeded in a
fresh plate and grown to confluence.
2.3. Peptides
PTH(1–34), TIP39 and rat [Nle8,21,Tyr34]rPTH(1–34)NH2 [called
rPTH(1–34) throughout this paper] were from Bachem (Saffronthe peptide agonist TIP-39 to the parathyroid hormone 2 (PTH2) receptor
harmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2016.12.013
Fig. 1. A. Sequence alignment of three Family B GPCRs: PTH2 (PTH2R_HUMAN); PTH1 (PTH1_HUMAN); and the glucagon receptor (GLR_HUMAN).The seven transmembrane
helices are boxed and are based on the crystal structure of the glucagon receptor [6]. The first and last residue number of each sequence is shown at the start and end of each
line respectively. The residues in PTH2 which were mutated to those of PTH1 are shown bold and underlined. B. A schematic topological representation (generated using
GPCRDB, http://gpcrdb.org) of PTH2, annotated to show the regions mutated in this study (grey) with the residue numbers of the most interesting site highlighted.
TM = transmembrane helix; ECL = extracellular loop.
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Table 1
cAMP assays of wild type PTH1 and PTH2, and 23 mutated PTH2 receptors substituted
at the sites indicated in Fig. 1 (single letter amino acid codes are shown here with
GPCRDB numbering in column 2 [29]). Values are the% of the mean maximal PTH(1–
34) response using either 1 lM PTH(1–34) left, or 10 nM TIP39 right. One residue (Tyr-
318-Ile) displays reduced TIP39 activity. **Significantly different to PTH2 (P 6 0.002).
Receptor GPCRDB numbering % maximum PTH(1–34) response
1 lM PTH(1–34) 10 nM TIP-39
PTH1 99 ± 2 1 ± 2
PTH2 102 ± 1 98 ± 2
PTH2R (V146 M) 1.41  41 102 ± 1 103 ± 1
PTH2R (M147I) 1.42  42 103 ± 2 100 ± 2
PTH2R (I154V) 1.49  49 104 ± 3 103 ± 5
PTH2R (V185L) 2.55  55 105 ± 2 104 ± 4
PTH2R (T192V) 2.62  62 102 ± 2 99 ± 1
PTH2R (I238V) 3.31  31 104 ± 2 97 ± 2
PTH2R (V241T) 3.34  34 100 ± 1 97 ± 2
PTH2R (M242F) 3.35  35 98 ± 2 98 ± 2
PTH2R (I244L) 3.37  37 100 ± 3 106 ± 4
PTH2R (A293V) 4.59  59 99 ± 2 97 ± 1
PTH2R (A295V) 4.61  61 99 ± 2 98 ± 1
PTH2R (V296S) 4.62  62 101 ± 2 101 ± 3
PTH2R (A297V) 4.63  63 100 ± 2 99 ± 1
PTH2R (Y318I) 5.39  39 99 ± 1 51 ± 6⁄⁄
PTH2R (A320V) 5.41  41 100 ± 1 97 ± 2
PTH2R (A325S) 5.46  46 103 ± 2 100 ± 2
PTH2R (G327V) 5.48  48 100 ± 2 99 ± 2
PTH2R (V380 M) 6.57  57 102 ± 1 102 ± 1
PTH2R (C381A) 6.58  58 100 ± 2 101 ± 2
PTH2R (L382T) ECL3 102 ± 2 103 ± 2
PTH2R (C397Y) 7.41  40 100 ± 2 98 ± 1
PTH2R (L399M) 7.43  42 101 ± 1 98 ± 2
PTH2R (F400L) 7.44  43 104 ± 2 105 ± 3
4 R.E. Weaver et al. / Biochemical Pharmacology xxx (2017) xxx–xxxWalden, UK). [Trp23,Tyr36]PTH(1–36) was custom synthesised by
Cambridge Research Biochemicals. The five truncated TIP39 pep-
tides (TIP (2–39), TIP (3–39), TIP (4–39), TIP (5–39), all with free
carboxyl C-termini, were custom synthesised by Genosphere
Biotechnologies (Paris, France) to >95% purity as analysed via RP-
HPLC (at 220 nm) and Mass Spec. The radioligand 125I-[Nle8,21,
Tyr34] rat PTH(1–34)NH2 (called 125I-rPTH(1–34) throughout the
paper) was from Perkin Elmer Life and Analytical Sciences (Wal-
tham, MA, USA).
2.4. Radioligand binding
HEK-293 cells expressing the receptor(s) of interest were grown
to confluence in poly-D-lysine coated 24-well plates. Radioligand
and unlabelled peptides were made up in ‘Whole Cell Binding Buf-
fer’ (WCBB: 100 nM NaCl, 50 mM Tric-HCl, 5 mM KCl, 2 mM CaCl2
pH 7.7; Sigma, Poole, UK) supplemented with 5% heat inactivated
horse serum and 0.5% heat inactivated foetal calf serum. The cell
culture media was removed and 150 lL of 125I-rPTH(1–34) was
then added to each well to give a final concentration of 50 pM
(50,000 cpm). 150 lL of serially diluted unlabelled ligand
(10 lM–10 pM) were then added to each well and the cells incu-
bated at room temperature for 2 h. The cells were then washed
three times with WCBB, lysed with 500 lL of 5 M NaOH, and then
the radioactivity in the cell lysate was measured in a gamma
counter.
2.5. cAMP accumulation assay
The LANCE cAMP kit (PerkinElmer Life and Analytical Sciences)
was used alongside the manufacturer’s instructions with some
minor adaptations as described. Cells were washed and resus-
pended in Stimulation buffer (HBSS, 5 mM HEPES, 0.1% BSA,
500 lM IBMX, pH 7.4; Sigma, Poole, UK) to the required concentra-
tion. The ligands were prepared in DMSO at 100-fold stimulation
concentrations and 0.1 lL added to each well of a white 384-well
low volume OptiPlate. 5 lL of cells were added to each well fol-
lowed by 5 lL of Stimulation buffer containing the Alexa Fluor
647-labelled antibody, and incubated at room temperature. After
the cell stimulation period, 10 lL of Detection mix was added to
each well and incubated for 1 h at room temperature. The data
shown in Tables 1–3 were generated by REW either at GSK (Tables
1 and 2) or Leeds (Table 3). The preliminary screening data in
Table 1 were derived using assay conditions of 10,000 cells/well
and a ligand stimulation time of 30 min, with 0.005 (v/v) Alexa Flu-
or. The acceptor fluorescence signal was read at 665 nm on a
ViewLux instrument (Perkin Elmer). Based on the results of this
screen, further mutagenesis of Tyr-318, followed by stable cell line
generation, were carried out and the full dose–response data
shown in Table 2 were generated using 5000 cells/well and a
ligand stimulation time of 20 min – the change in conditions was
required to reduce the assay sensitivity in order to fit within the
window of the standard cAMP curve generated using the assay
kit at that time. The truncated TIP39 data shown in Table 3 were
generated at a later stage in Leeds and the conditions were also
modified in order to fit within the window of the standard cAMP
curve: 2500 cells/well and a ligand stimulation time of 10 min,
with 0.0025 (v/v) Alexa Fluor, read at 665 nm (Victor X4 plate-
reader, Perkin Elmer). Note that data have only been directly com-
pared within each table for which assay conditions were identical.
2.6. Data analysis
For each individual competition binding experiment, counts
were normalised to the maximal specific binding within each data
set. IC50 values were calculated with a single site binding modelPlease cite this article in press as: R.E. Weaver et al., High affinity binding of
requires the hydroxyl group of Tyr-318 on transmembrane helix 5, Biochem. Pwith the Hill co-efficient constrained to 1, while EC50 values were
calculated with a symmetrical sigmoid function, using non-linear
regression with the aid of PRISM 5.0 software (GraphPad Software
San Diego, CA, USA). Values in the tables represent the mean with
S.E.M. of the individual pIC50 (Log IC50) or pEC50 values from at
least three independent experiments, each of which was carried
out with triplicate vales for each ligand concentration. Compar-
isons with controls were assessed using a two-tailed unpaired t
test using GraphPad. Curves in the figures represent pooled data
from three independent experiments where each point is the mean
of the normalised values with the inter-experimental standard
error of the mean displayed as error bars. Bmax values were calcu-
lated from rPTH(1–34) homologous binding assays using Bmax = -
B0  IC50/[L], where [L] is the concentration of free radioligand
and B0 is the specific binding in the absence of unlabelled ligand.
Bmax values were expressed as fmol of receptor per mg of mem-
brane protein where the latter was calculated using a bicinchoninic
acid protein assay using bovine serum albumin to create a standard
curve.2.7. Modelling method
2.7.1. Agonist-bound PTH2 receptor model
All molecular modelling manipulations were carried out using
the tools embedded within PyMOL (The PyMOL Molecular Graph-
ics System, Version 1.7.2.3 Schrödinger, LLC) unless otherwise sta-
ted. The first stage was to make a homology model of the J domain
of PTH2 from the crystal structure of the J domain of the glucagon
receptor ([6]; pdb code 4L6R) using the homology modelling server
SWISS-MODEL ([22]; http://swissmodel.expasy.org/). In an inde-
pendent step, the ligand within the PTH-bound N domain crystal
structure of PTH1 ([4]; pdb code 3C4M) was mutated in silico to
the sequence of TIP39 (starting at Ala-15⁄) and the N domain of
PTH2 was built from 3C4M using SWISS-MODEL. Since the ligand
co-ordinates were stripped out during the homology modellingthe peptide agonist TIP-39 to the parathyroid hormone 2 (PTH2) receptor
harmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2016.12.013
Table 2
Pharmacological data for various peptide ligands at wild type PTH2 and three mutated PTH2 receptors, as indicated. Values represent mean pEC50 and pIC50 values ± S.E.M. for
three independent experiments, with the corresponding EC50 or IC50 values (nM) shown below in brackets. Bmax were derived from three independent homologous radioligand
competition binding assays using the radioligand 125I-rPTH(1–34). Significantly different from PTH2 with the TIP-39: *P 6 0.02; **P 6 0.002).
pEC50
(EC50/nM)
pIC50
(IC50/nM)
Bmax
/amol cell1
PTH(1–34) Trp23-PTHrP TIP-39 TIP-39
PTH2 8.39 ± 0.28
(4.1)
ND 9.14 ± 0.35
(0.7)
7.81 ± 0.02
(15.5)
13.3 ± 2.4
Tyr-318-Phe 8.17 ± 0.30
(6.8)
5.84 ± 0.15
(1445.4)
7.60 ± 0.22⁄
(25.1)
6.70 ± 0.16⁄⁄
(199.5)
10.7 ± 2.4
Tyr-318-Leu 8.66 ± 0.22
(2.2)
6.09 ± 0.20
(812.8)
6.50 ± 0.09⁄⁄
(316.2)
6.17 ± 0.08⁄⁄
(676.1)
12.3 ± 2.2
Tyr-318-Ile 9.45 ± 0.08
(0.4)
7.39 ± 0.08
(40.7)
6.69 ± 0.03⁄⁄
(204.2)
6.02 ± 0.03⁄⁄
(955.0)
21.3 ± 7.7
Table 3
Pharmacological data for TIP39 and N-terminally truncated analogues (see Fig. 4A) at
wild type PTH2 and two mutated PTH2 receptors, as indicated. Values represent mean
pEC50 and pIC50 values ± S.E.M. for three independent experiments, with the
corresponding EC50 or IC50 values (nM) shown below in brackets. Significantly
different from TIP39 at the same receptor: ⁄ P 6 0.02; ⁄⁄ P 6 0.002).
pEC50
(EC50/nM)
PTH2 Tyr-318-Phe Tyr-318-Ile
TIP-39 10.24 ± 0.07 9.18 ± 0.04 8.18 ± 0.09
(5.75  102) (0.66) (6.61)
TIP (2–39) 9.92 ± 0.10 8.32 ± 0.11⁄⁄ 7.38 ± 0.17⁄
(0.12) (4.79) (41.69)
TIP (3–39) 9.66 ± 0.13⁄ 8.02 ± 0.11⁄⁄ 7.30 ± 0.17⁄
(0.22) (9.55) (50.12)
TIP (4–39) 9.54 ± 0.14⁄ 7.88 ± 0.20⁄ 7.05 ± 0.14⁄
(0.29) (13.18) (89.13)
TIP (5–39) 7.77 ± 0.06⁄⁄ 6.04 ± 0.18⁄⁄ <6
(16.98) (912.01) (>1000)
TIP (6–39) 6.91 ± 0.16⁄⁄ <6 ND
(123.03) (>1000)
pIC50
(IC50/nM)
PTH2 Tyr-318-Phe Tyr-318-Ile
TIP-39 7.81 ± 0.02 6.70 ± 0.16 6.02 ± 0.03
(15.49) (199.53) (954.99)
TIP (2–39) 7.23 ± 0.15⁄ 6.38 ± 0.10 5.83 ± 0.12
(58.88) (416.87) (1479.11)
TIP (3–39) 6.98 ± 0.10⁄⁄ 6.32 ± 0.09 5.90 ± 0.11
(104.71) (478.63) (1258.93)
TIP (4–39) 6.80 ± 0.04⁄⁄ 6.22 ± 0.11 5.83 ± 0.13
(158.49) (602.56) (1479.11)
TIP (5–39) 6.06 ± 0.08⁄⁄ 5.49 ± 0.10⁄ 5.14 ± 0.08⁄⁄
(870.96) (3235.93) (7244.36)
TIP (6–39) 5.98 ± 0.07⁄⁄ 5.37 ± 0.09⁄⁄ 5.06 ± 0.04⁄⁄
(1047.13) (4265.78) (8709.63)
R.E. Weaver et al. / Biochemical Pharmacology xxx (2017) xxx–xxx 5stage, these TIP39 and PTH2 fragments were then re-docked by
superposing them back on the 3C4M template. The Dods and Don-
nelly model [16] of the agonist-bound GLP-1 receptor was then
used as a scaffold from which the full-length TIP39-bound PTH2
was constructed by first superimposing the PTH2 J domain model
onto the corresponding 7TM region of GLP-1R, and then superim-
posing the TIP39 ligand on the GLP-1 peptide and, in doing so, ori-
entating the N domain relative to the J domain. The merged
fragments were saved as a single pdb file and then used as a tem-
plate in SWISS-MODEL from which PTH2 was rebuilt, enabling the
linker region between the domains to be constructed as a loop.
Since the ligand co-ordinates were stripped out during the homol-
ogy modelling stage, TIP39 was re-docked according to the 3C4M
template and then manually extended along the GLP-1R peptide
model trajectory. Two main constraints were used to guide the lat-
ter stage: (1) since Arg-190 and Lys-197 are conserved betweenPlease cite this article in press as: R.E. Weaver et al., High affinity binding of
requires the hydroxyl group of Tyr-318 on transmembrane helix 5, Biochem. PGLP-1R and PTH2, and are believed to interact with Glu-3 in the
former [see 16–19], the equivalent residue in TIP39 (Asp-6) was
positioned in a similar position; (2) Ala-3 (equivalent to the first
residue of PTH) was placed close to residues 376, 379 and 380,
since the equivalent residues in PTH1 have been cross-linked to
the extreme N-terminus of PTH [10]. The first loop of the N domain
was constructed using PLOP [23] and model was then subjected to
optimisation using the KoBaMIN server ([24]; http://csb.stanford.
edu/kobamin) to yield the starting model for molecular dynamics
simulations.
2.7.2. Molecular dynamics simulations
Simulations of PTH2 in complex with two variants of TIP39 were
prepared as follows. All the PTH2-TIP-39 complexes were embed-
ded in a POPC bilayer with explicit water and ions to a final con-
centration of 150 mM, and simulated using ACEMD [25], with the
AMBER 14SB [26] and lipid 14 force fields [27]. The simulation pro-
tocol included standard steps of energy minimization, heating
from 0 to 300 K, and progressive decrease of conformational con-
straints followed by the unconstrained production run. Simulation
1 contained the full TIP39 peptide and the production run was
442 ns. However, due to uncertainties in predicting the starting
conformation of the N-terminal region of full length TIP-39, we
decided to simulate variants of TIP39 with a truncated N-
terminus. Simulation 2 contained PTH2 bound to TIP (5–39), and
the production run was 250 ns. Simulation 3 contained PTH2 with
the Tyr318-Ile mutation and TIP (5–39) peptide, the production
run was 140 ns. The initial systems dimensions and sizes were
88.31 Å  88.68 Å  138.24 Å with 98,594 atoms for simulation
1, 88.03 Å  88.39 Å  134.24 Å with 95,089 atoms for simulation
2, and 88.31 Å  88.39 Å  142.24 Å with 101,659 atoms for simu-
lation 3. Hydrogen bonds were defined with a donor–acceptor dis-
tance <3.0 Å, and an angle cut-off of 20. The models and
trajectories are available from ftp.essex.ac.uk/pub/oyster.
3. Results
3.1. Initial pharmacological screen
A total of 25 stable cell lines were created for the initial screen,
expressing either wild type PTH1, PTH2, or one of 23 mutant PTH2
receptors. Table 1 shows the response generated from LANCE cAMP
assays using concentrations of PTH(1–34) and TIP39 which had
been shown to generate maximal responses in full concentration
response experiments using these particular assay conditions (data
not shown). As expected, PTH(1–34) was able to fully activate both
PTH1 and PTH2, as well as all the 23 single mutant PTH2 receptors.
TIP39 was unable to activate PTH1 but displayed maximal activity
at 22 of the 23 mutant PTH2 receptors, the exception being Tyr-
318-Ile which displayed only about 50% maximal activity.the peptide agonist TIP-39 to the parathyroid hormone 2 (PTH2) receptor
harmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2016.12.013
Fig. 2. cAMP accumulation curves for HEK-293 cells expressing A PTH2 and B Tyr-
318-Ile, using three peptide ligands as indicated in the key. Curves represent pooled
data from three independent experiments where each point is the mean of the
normalised values and inter-experimental standard error of the mean is displayed
as error bars.
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The mutant PTH2 receptor, Tyr-318-Ile, was examined in more
detail by using whole-cell radioligand binding assays and by gen-
erating full concentration–response curves using PTH(1–34),
TIP39 and the affinity-optimised PTHrP analogue, Trp23-PTHrP
(Table 2 and Fig. 2). The typical pharmacological profile of PTH2
was observed (Fig. 2A), with high potency displayed for PTH(1–
34) and TIP39 but no activity with Trp23-PTHrP. However, the
pharmacological profile for Tyr-318-Ile was radically different
(Fig. 2B). As shown previously [15,20], Tyr-318-Ile could be acti-
vated by Trp23-PTHrP while maintaining high potency for PTH
(1–34). However, as indicated by the initial screen, TIP39 potency
was compromised and reduced by almost 300-fold. Radioligand
binding assays showed that the affinity of TIP39 had been reduced
by >60-fold due to the Tyr-318-Ile mutation (Table 2).
3.3. Additional mutations at Tyr-318
In order to explore the nature of the pharmacological effects
caused by the mutation of Tyr-318 to Ile, the site was further
mutated to both Phe and Leu. Radio-ligand binding and LANCE
cAMP assays showed that the Tyr-318-Leu mutation resulted in a
similar TIP39 profile as Tyr-318-Ile. However, as expected, the
more subtle change from Tyr to Phe resulted in a less severe effect
compared with the substitution to Ile upon TIP39 affinity (13-fold
compared with 62-fold) and potency (35-fold compared with 282-
fold). Nevertheless, the reduced affinity and potency of Tyr-318-
Phe compared with PTH2 suggested that the hydroxyl group of
Tyr-318 plays a role in endogenous ligand recognition (Table 2,
Fig. 3).
3.4. N-terminal truncations of TIP39
In order to explore whether Tyr-318, and in particular its hydro-
xyl group, interacts with the N-terminal residues of TIP39, 5 N-
terminal truncations of the peptide (Fig. 4A) were pharmacologi-
cally analysed at PTH2, Tyr-318-Ile and Tyr-318-Phe (Table 3).
Truncation of up to 3 residues at the N-terminus of TIP39 resulted
in up to only a 5-fold reduction in potency but the removal of the
4th residue (Leu-4⁄) resulted in a step-change reduction of almost
300-fold. Likewise, TIP39 missing the first 5 N-terminal residues
had >2000-fold lower potency compared with full-length TIP39
(Fig. 4B). The reduction in potency observed for peptides lacking
residues 4 and 5, is only partly correlated with a reduction in affin-
ity, with a much smaller step change (68-fold for affinity compared
with 2138-fold for potency; Table 3; Fig. 4B and C). The truncated
TIP39 peptides displayed a similar profile at Tyr-318-Phe and Tyr-
318-Ile, albeit with right-shifted curves, demonstrating that the
mutations had affected all the peptides to a similar degree and that
peptides lacking residue 4, or residues 4 & 5, have severely
impaired potency at both the wild type and mutant receptors
(Table 3, Fig. 4).
3.5. Molecular modelling and molecular dynamics simulations
The initial starting model for the TIP39-PTH2 complex resem-
bled that of the GLP-1R template used [16] in terms of the relative
positioning of the N and J domains and on the placement of the
helical region of the peptide ligand. However, while the N-
terminal region of the ligand in the GLP-1R template was modelled
on the b-coil region of the related ligand PACAP21 (pdb code
1GEA), the absence of sequence conservation in TIP39 and its
longer length (3 residues longer than GLP-1) resulted in the need
to build this region ab initio, with the guidance of two constraints.
Firstly, the Glu-9⁄ to Arg-190 interaction [16,19] between GLP-1Please cite this article in press as: R.E. Weaver et al., High affinity binding of
requires the hydroxyl group of Tyr-318 on transmembrane helix 5, Biochem. Pand GLP-1R was emulated in the TIP-39-PTH2 model through an
interaction between Asp-6⁄-Arg-190 and, indeed, this interaction
was maintained in the dynamics simulation (Fig. 6C), in the same
way as the analogous interaction was also stable in simulations
of GLP-1R with GLP-1 [19]. Secondly, Ala-3⁄ in TIP39 (equivalent
to the first residue of PTH) was placed close to PTH2 residues
376, 379 and 380, since the extreme N-terminus of PTH has been
cross-linked to these sites in PTH1 [10]. However, the ambiguity
and sporadic nature of the initial simulations of full-length PTH2
bound to full-length TIP-39 (data not shown) led us to believe that
the subjective modelling of the peptide’s extreme N-terminus was
problematic. To address this, we prepared further simulations of
PTH2 with a truncated N-terminus, TIP (5–39), which showed a
stable pattern of hydrogen bonding of Tyr-318 with residue Asp-
7⁄ of TIP39 (Figs. 5 and 6).
In addition to the Asp-6⁄-Arg190 (2.60  60, [29]) interaction,
the molecular dynamics predicted a number of other interactionsthe peptide agonist TIP-39 to the parathyroid hormone 2 (PTH2) receptor
harmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2016.12.013
Fig. 3. A. cAMP accumulation and B. radioligand competition binding assay, both
using TIP39 at HEK-293 cells expressing PTH2, Tyr-318-Ile, Tyr-318-Leu or Tyr-318-
Phe, as indicated in the key. Curves represent pooled data from three independent
experiments where each point is the mean of the normalised values and inter-
experimental standard error of the mean is displayed as error bars.
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icant frequency during the simulations (Fig. 7). For example, the
hydrogen bond between Asp-7⁄ and Tyr-318 (5.39  39) is supple-
mented by an additional interaction between the Asp-7⁄ and Gln-
319 (5.40  40). Arg13⁄ can interact with either with Gln-138
(1.33  33) or Glu-139 (1.34  34) at the top of TM1, and also with
Glu-392 (7.49  49) at the top of TM7. In addition, hydrophobic
interactions were observed between Ala-9⁄ and Leu-399
(7.43  42) and between Phe-10⁄ and Phe-141 (1.36  36).4. Discussion and conclusions
Both human PTH1 and PTH2 receptors are activated by PTH, sug-
gesting that they share similar ligand binding sites and are acti-
vated by equivalent mechanisms. However, TIP39, the potent
PTH2 agonist and endogenous PTH2 ligand, does not appreciably
activate PTH1, despite binding to it with moderate affinity [21].
Chimeric PTH1/PTH2 receptors, in which the N and J domains were
exchanged, have been used to demonstrate that it is the J domain
which is responsible for interacting with the N-terminal region ofPlease cite this article in press as: R.E. Weaver et al., High affinity binding of
requires the hydroxyl group of Tyr-318 on transmembrane helix 5, Biochem. PTIP39 and for providing the observed selective binding [13,14].
Hence, we have substituted selected PTH2 residues with those
found in PTH1 and have identified Tyr-318 as the key residue posi-
tion responsible for the observed reduction in reduced TIP39 activ-
ity. The results of the modelling and molecular dynamic
simulations suggest that the N-terminus of the peptide binds
within the helical bundle of the J domain, and that Asp-7⁄ is the
most likely interaction partner of Tyr-318 since its hydroxyl group
can form an hydrogen bond with the carboxylate group of Asp-7⁄,
which persists during the MD simulations on the truncated pep-
tide, TIP39(5–39), despite the dramatically reduced affinity of this
peptide.
Residues predicted to be close to the extracellular ends of the
TM regions of PTH2, and which were not conserved between
PTH1 and PTH2, were targeted for site-directed mutagenesis. The
start of this study preceded the solution of the first crystal struc-
tures of the J domain [5–7], and hence the TM boundaries were
predictions but nevertheless largely match those revealed by the
crystal structures (Fig. 1; TM boundaries shown are based on
[6]). The 23 mutant receptors generated were screened using a
cAMP assay in order to identify any mutations which had reduced
TIP39 activity. As expected, given that both human PTH1 and PTH2
are activated by PTH, all the mutant receptors maintained full
activity when exposed to 1 lM PTH. In hindsight, given the subse-
quent publication of the crystal structures, many of the residues
targeted were facing away from the centre of the helical bundle
and hence would be expected not to contribute directly to peptide
binding. However, of the 6 internally-facing residues targeted for
mutagenesis, only the Tyr-318-Ile mutation displayed reduced
activity to 10 nM TIP39 and was hence examined in more detail.
Tyr-318-Ile in PTH2 has been identified previously as one of two
sites responsible for enabling the receptor to select against PTHrP,
probably through interacting with residue 5 of PTH and PTHrP [15].
Using Trp23-PTHrP (the Phe-23⁄ to Trp modification enables
higher affinity binding to PTH2 [13,15]), the ability of the Tyr-
318-Ile mutation to enable Trp23-PTHrP activation can be clearly
observed using full concentration response curves (Fig. 2). How-
ever, we show for the first time here that the same mutation
results in a substantial reduction in TIP39 potency (>280-fold)
and affinity (>60-fold), yielding a receptor with substantially
altered pharmacology from wild type PTH2 (compare
Fig. 2A and B).
In order to explore the mechanism underlying this altered phar-
macological profile, we examined two further substitutions of Tyr-
318, mutated to Phe and Leu, using radioligand binding assays and
functional cAMP assays. Both Tyr-318-Leu and Tyr-318-Phe dis-
played high potency for PTH(1–34) and also rescued potency for
Trp23-PTHrP, albeit both at a lower potency compared with Tyr-
318-Leu, which has the substitution to the native PTH1 residue
(Table 2). The Tyr-318-Leu receptor displayed similarly impaired
TIP39 pharmacology as Tyr-318-Ile, with a TIP39 potency reduc-
tion of 437-fold and affinity reduction of 44-fold. The more subtle
substitution of Tyr-318 with Phe, removing a single hydroxyl
group, nevertheless resulted in a mutant receptor with 35-fold
reduced potency and 13-fold reduced affinity for TIP39 compared
with wild type PTH2. Hence we conclude that Tyr-318 takes part
in an interaction that optimises the binding and activation pocket
for TIP39 and that its hydroxyl group forms part of this interaction.
Given that the truncation of the first 6 residues of TIP39, to yield
TIP (7–39), resulted in a peptide with no observable efficacy at
PTH2 [21], we explored the possibility that the interaction formed
by Tyr-318 may be via these first 6 residues. Indeed, the removal of
4 or 5 residues from TIP39 resulted in a peptide with a reduced
affinity that approximates (about 60-fold) to that observed when
the hydroxyl group of Tyr-318 is removed (Tables 2 and 3). We
hypothesised that a direct interaction between PTH2 and athe peptide agonist TIP-39 to the parathyroid hormone 2 (PTH2) receptor
harmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2016.12.013
Fig. 4. A Sequence alignment of TIP39 and the five N-terminally truncated analogues used in this study. B/D cAMP accumulation assays and C/E radioligand competition
binding assays, both using HEK-293 cells expressing B/C PTH2 or D/E Tyr-318-Phe. The ligands used are indicated in the key in A. Curves represent pooled data from three
independent experiments where each point is the mean of the normalised values and inter-experimental standard error of the mean is displayed as error bars.
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the removal of that residue led to no detectable change in affin-
ity/potency when comparing wild type PTH2 and a Tyr-318
mutant: – the logic being that if the interacting residue was
already absent from the ligand (due to truncation), then the
removal of the Tyr-318 interaction site would result in no addi-
tional change in affinity/potency. However, the Tyr-318-Ile and
Tyr-318-Phe mutations affected all the truncated TIP39 analogues
used, including TIP (6–39), suggesting that Tyr-318 interacts with a
residue within the 6–39 region. The absence of potency for TIP39
peptide analogues truncated beyond this point [21] makes it diffi-
cult to explore this possibility experimentally, and hence we have
used a computational approach to explore the hypothesis that Tyr-
318 may interact with Asp-7⁄, the topologically equivalent site to
reside 5⁄ of PTH and PTHrP that has previously been shown to be
functionally linked to Tyr-318 [15]. There had been an earlier
attempt [28] to model TIP39 binding to PTH2 which suggested that
Asp-7⁄ interacts with His-396 on TM7. However, this study pre-
dated the solution of the structure of any Family B J domain and
the new information suggests that His-396 is positioned at the
TM1-TM7 interface and quite distant from Asp-7⁄. Our modelling
has enabled the predictions of a dual interaction between Asp-6⁄Please cite this article in press as: R.E. Weaver et al., High affinity binding of
requires the hydroxyl group of Tyr-318 on transmembrane helix 5, Biochem. Pand Arg-190 and between Asp-7⁄ and Tyr-318 which, coupled with
the cross-linking data [8–10], makes the PTH1/PTH2 system partic-
ularly well characterized for class B receptors. Truncation of Asp-6⁄
led to a complete loss of activity [21] and our model suggests it
plays a key role through binding to Arg190 – indeed, this interac-
tion may be quite general amongst class B GPCR ligands as several
have a residue similar to Asp-6⁄ at this position [30].
In summary, we have analysed 23 sites within the PTH2 recep-
tor and identified Tyr-318 as playing an important role in the inter-
action of the endogenous TIP39 agonist with its receptor, given
that its substitution with Ile or Leu results in a 282–437-fold
reduction in potency and a 44–62-fold reduction in affinity. The
hydroxyl group of Tyr-318 is involved in this interaction since its
removal resulted in a 35-fold reduced potency and 13-fold reduced
affinity for TIP39. To our knowledge, this is the first reported PTH2
receptor residue shown to interact with its endogenous agonist
TIP39 and its identification, alongside our model based upon the
latest crystallographic data for Family B GPCRs, enabled us to sug-
gest a binding model for the N-terminus of TIP39 within the TM
domain of PTH2. The interaction of Tyr-318 is likely to be with
the N-terminal region of TIP39, although not with residues 15.
Given the outcome of the molecular modelling and molecularthe peptide agonist TIP-39 to the parathyroid hormone 2 (PTH2) receptor
harmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2016.12.013
Fig. 5. A. An overlay of the starting model of PTH2 bound to TIP (5–39) (green and orange), with the model following molecular dynamics simulations (cyan and yellow). B.
Time dependent root mean square deviation (RMSD) of the backbone atoms for the full model (blue), the TM helices (black) and the N domain (orange) following molecular
dynamics simulations (cyan and yellow in A) in relation to the starting structure (green and orange in A). C. Distance over time during molecular dynamics simulations
between residue 318 (hydroxyl oxygen atom for Tyr or CD1 atom for Ile) and Asp-7 (CD atom) of TIP39 in the wild type (green) and mutant Tyr318-Ile (red) receptors. In
Tyr318-Ile, Ile-318 does not interact with Asp-7 whereas in wild type Tyr318 and Asp-7 approached to form a stable hydrogen bond. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
A B
C Asp7*-Tyr318
Asp6*-Arg190
Asp7*
Asp6*
Tyr318
Arg190
Fig. 6. A. The model from molecular dynamics simulations of PTH2 bound to TIP (5–39), shown in ribbon form with PTH2 (cyan) docked with TIP-39 (yellow). The boxed area
shows the region detailed further in B., showing interactions (dashed line with distances in Å) of Asp-6⁄ and Asp-7⁄ with the receptor. C. Time-dependent number of hydrogen
bonds formed during molecular dynamics simulations of PTH2 bound to TIP (5–39) between the indicated residues. Cut off values for hydrogen bonds were donor acceptor
distance <3.0 Å, and 20 for angle. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
R.E. Weaver et al. / Biochemical Pharmacology xxx (2017) xxx–xxx 9dynamics study, coupled with alignment of Asp-7⁄ in TIP39 with
His-5⁄ in PTHrP and Ile-5⁄ in PTH, we propose that the most likely
candidate to interact with Tyr-318 is Asp-7⁄. The simulations also
identified Asp-6⁄ as a likely binding partner of Arg-190, as also
observed in GLP-1R [16] and in the VPAC receptor [31,32].Please cite this article in press as: R.E. Weaver et al., High affinity binding of
requires the hydroxyl group of Tyr-318 on transmembrane helix 5, Biochem. PAuthor contributions
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